The net value of medical funds has surged significantly, while institutional allocation remains at a historically low level.

Recently, the A-share market has seen a shift in style, with the previously strong technology sector undergoing adjustments, while the long-quiet pharmaceutical sector has begun a robust rebound. Many actively managed pharmaceutical funds have significantly increased in value, becoming a bright spot in the market. According to Wind data, as of August 14, several actively managed equity pharmaceutical funds have seen returns surpassing 30%, with leading products performing particularly well. Among them, China Merchants Frontline Healthcare, China Merchants Pharmaceutical Health Industry, and Huatai-PB Healthcare have seen increases of over 54%, 53%, and 52%, respectively, leading their category of pharmaceutical funds; other products such as Harvest Medical Healthcare and GF Pharmaceutical Selection have risen by more than 40%. Over a dozen pharmaceutical-themed funds, including CCB High-end Medical, China Europe Medical Innovation, and Guotai Innovation Pharmaceutical, have all exceeded 30% in gains, demonstrating a significant overall profitability effect. Industry analysts suggest that the current pharmaceutical market is driven by industrial trends and structural opportunities, and has not yet entered a phase of capital grouping or market congestion. Fund values have rebounded first, but ETF funds and overall institutional holdings have not yet followed suit with additional purchases, indicating a clear low-position characteristic in the sector. If the industry's fundamental catalysts continue to materialize and corporate performance continues to meet expectations, the current low proportion of institutional allocation will provide ample space for subsequent incremental capital to flow back and for the sector's trend to continue upward.